The Invisible Burden of a Visible Disease: Exploring Psychosocial Burden and Quality of Life Impairment in Vitiligo

Background Vitiligo is a chronic autoimmune disease characterized by patches of depigmentation on the skin or hair, or both, with an estimated global prevalence ranging from 0.4 to 2%. Beyond its visible manifestations, vitiligo is associated with emotional distress, social challenges, and impairments in work productivity, daily activities, and overall health-related quality of life. However, the extent of this burden varies substantially and may be moderated by multiple factors, such as lesion visibility, internalized social stigma, and learned coping mechanisms. This study examined how psychosocial burden varies across these factors among adults with vitiligo in the United States (US) and Europe. Methods An online cross-sectional survey was administered to adults with vitiligo in the US and Europe (United Kingdom, Germany, France, Italy, and Spain). Patient-reported vitiligo disease burden was assessed using the Vitiligo Impact Patient Scale (VIPS), a 29-item validated instrument measuring the psychosocial burden and quality of life of vitiligo across four domains: psychosocial functioning, social functioning, relationship functioning, and treatment burden7. VIPS scores range from 0 to 95 with higher scores equating to a greater burden. VIPS scores were stratified by patient-reported vitiligo severity on face (none, mild, moderate, severe, very severe), severity on body (none, mild, moderate, severe, very severe), years since initial diagnosis (≤5, >5 years), and severity of vitiligo-related stigma (mild, moderate to severe). Stigma was measured using the Patient Unique Stigmatization Holistic Tool in Dermatology (PUSH-D), a 17-item validated instrument assessing felt stigma and enacted stigma. Significant associations were evaluated using Chi-squared tests (p<0.05). Results 122 adults were analyzed with a mean age of 58 years and 51% were female. The mean (SD) VIPS score was 20.4. (24.1). VIPS scores were higher among adults with moderate-to-very severe facial vitiligo (36.7 [27.26]) compared to those with none-to-mild facial vitiligo (9.9 [14.01]; p < 0.001). Those reporting moderate to very severe vitiligo on the body also had higher VIPS scores (28.2 [25.6]) than those with none to mild severity on the body (8.1 [14.6]; p < 0.001). Shorter disease duration (time since initial diagnosis) was significantly associated with a higher VIPS score (≤ 5 years; 32.4 [29.1]) compared to those with a longer disease duration (>5 years; 15.4 [19.8]; p = 0.002). Respondents reporting moderate to severe stigma (PUSH-D score ≥14) also reported significantly higher VIPS scores (51.4 [22.4]) than those with mild internalized stigma (PUSH-D score <14; 9.4 [12.0]; p < 0.001). Conclusion Vitiligo-related psychosocial burden, as measured by the VIPS, was significantly greater in adults with more severe disease on the face and body, a shorter disease duration, and greater perceived vitiligo stigma. These findings suggest that visibility and self-perceived severity may contribute to worsened psychosocial outcomes. Additionally, early disease may represent a period of heightened vulnerability for QOL impacts, and over time, individuals may develop coping mechanisms to manage psychosocial impacts. These findings point to the need for early disease management strategies to address symptoms of the disease to potentially mitigate downstream quality of life impacts.